Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
541-560 of 936 trials

BI 3804379: Tolerance Study in Healthy Volunteers

We are testing how well different doses of BI 3804379 are tolerated by healthy people. This study aims to gather important safety information for future use in patients.

Healthy Volunteers1-2 yearsSafety phase (I)

Malignant Solid Tumors: GEN1057 Treatment

We are assessing the safety and potential effectiveness of GEN1057 for individuals with malignant solid tumors. This trial aims to see how well it works compared to current treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

YTB323 for Treatment-Resistant Generalized Myasthenia Gravis

We are studying the safety and effects of YTB323 in patients with treatment-resistant generalized myasthenia gravis. This research aims to understand how the drug works in the body and its potential to improve symptoms.

Myasthenia Gravis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Pulmonary Arterial Hypertension: LTP001 Treatment Study

We are studying a new treatment called LTP001 in healthy adults and in individuals with pulmonary arterial hypertension. The goal is to evaluate its safety and how well it may improve exercise capacity and overall health.

Pulmonary Arterial HypertensionSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Advanced Solid Tumors: MCLA-158 (Petosemtamab) Study

We are testing a new treatment called MCLA-158 for people with advanced solid tumors to see how well it works and how safe it is. This study looks at its effects alone and in combination with other therapies.

Metastatic Colorectal CancerMalignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Glioblastoma: Radioimmunotherapy with Lutetium 177

We are investigating a new treatment using a targeted antibody for patients with glioblastoma. The study aims to determine the right dose and assess its safety and effectiveness.

Glioblastoma1-2 yearsSafety phase (I)NeurologyOncology

Retinitis Pigmentosa: Stem Cell Eye Treatment

We are testing a new stem cell-based treatment for people with retinitis pigmentosa to see if it is safe and tolerable. The study also aims to evaluate its potential to improve vision.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Advanced Solid Tumors: GSK5764227 Study

We are testing a new drug, GSK5764227, in people with advanced solid tumors to see how safe it is and how it affects their condition. This study aims to gather important information for future treatments.

Neoplasms1-2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: Anti-GD2 ADC M3554

We are testing a new treatment for patients with advanced solid tumors to see if it can improve their condition. This study aims to evaluate the safety and effectiveness of the drug.

Soft Tissue SarcomaGlioblastomaAdvanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: Saruparib Study

We are investigating how the drug saruparib works and its safety in adults with advanced solid tumors. This trial aims to provide insights into its potential benefits for patients.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Prostate Cancer: 225Ac-PSMA I&T Treatment

We are testing a new radioactive treatment for men with prostate cancer. This study aims to evaluate its safety and how well it works.

Metastatic Prostate Cancer>2 yearsSafety phase (I)Oncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Karonudib for Blood Cancers: Phase 1 Study

We are evaluating the safety and tolerability of Karonudib in patients with advanced blood cancers like Acute Myeloid Leukemia and Multiple Myeloma. This study aims to find the best dose and understand how well it works with other cancer treatments.

Blood Cancers>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Kidney Transplant: Eight Treg Immunotherapy

We are testing a new treatment using expanded regulatory T cells for living donor kidney transplant recipients. The goal is to see if this approach is safe and may reduce the need for traditional immunosuppressive medications.

Chronic Kidney FailureSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Knee Surgery Pain Relief: Nefopam Study

We are investigating whether an oral medication called nefopam can reduce morphine use after total knee replacement surgery. This study aims to improve pain management for adults recovering from this procedure.

Postoperative Pain After Knee Surgery>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineOrthopedics and Traumatology

Solid Tumors: PET Imaging of Vartumabs

We are exploring how two types of Vartumabs are seen in PET scans for patients with solid tumors. This study aims to gather early information about their behavior in the body.

Malignant Solid TumorsSafety phase (I)Oncology

Advanced Solid Tumors: GSK5733584 Injection

We are evaluating a new injection for people with advanced solid tumors to see if it is safe and how well it works. This study aims to understand the drug's effects on patients.

Ovarian Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Pancreatic Cancer: TCR-Modified T-Cell Therapy

We are studying a new therapy using modified T-cells for adults with advanced pancreatic cancer that has specific genetic mutations. The trial aims to assess safety and how well this treatment may work.

Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Rectal Cancer: Valproic Acid with Radiotherapy and Capecitabine

We are studying whether adding valproic acid to standard radiotherapy and capecitabine improves tumor response in patients with low to moderate risk rectal cancer before surgery. This trial also examines the impact on survival and quality of life.

Rectal CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

HIV Treatment: IMC-M113V Study

We are evaluating a new treatment, IMC-M113V, for people with chronic HIV infection who are already on medication. The study will help us understand its safety and how it affects the immune system.

Chronic HIV Infection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine